Coherus Biosciences | CHRS - Selling And Administration Expenses


Coherus Biosciences reported $15M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 264.59M 77.4M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Baxter International USD 728M 33M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Fujifilm JPY 236.14B 20.3B Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Merck USD 2.67B 180M Mar/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026
Xencor USD 82.12M 65.08M Mar/2026
Zoetis USD 588M 31M Mar/2026